Malignant neoplasm of lung
|
0.800 |
Biomarker
|
disease |
BEFREE |
TP53, EGFR and PIK3CA gene variations observed as prominent biomarkers in breast and lung cancer by plasma cell-free DNA genomic testing.
|
31100334 |
2019 |
Malignant neoplasm of lung
|
0.800 |
Biomarker
|
disease |
BEFREE |
Co-occurring genomic alterations, particularly in tumour suppressor genes such as TP53 and LKB1 (also known as STK11), have emerged as core determinants of the molecular and clinical heterogeneity of oncogene-driven lung cancer subgroups through their effects on both tumour cell-intrinsic and non-cell-autonomous cancer hallmarks.
|
31406302 |
2019 |
Malignant neoplasm of lung
|
0.800 |
Biomarker
|
disease |
BEFREE |
LIMCH1 was a negative regulator and indicated a new molecular mechanism for the pathogenesis of lung cancer via modulating HUWE1 and p53.
|
31279706 |
2019 |
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
TP53 mutations with 0.05-1.0% VAF were more prevalent (p < 0.05) and also enriched for tobacco smoke and age-associated mutation signatures in normal AEC from lung cancer cases compared to non-cancer controls matched for smoking and age.
|
31711466 |
2019 |
Malignant neoplasm of lung
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
The present study was aimed to explore the effect of S100A6 on the proliferation, invasion, migration and angiogenesis in lung cancer cell lines with the change of miR-193a expression and P53 acetylation.
|
31497188 |
2019 |
Malignant neoplasm of lung
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Less expression of p53 or p53 mutation was identified in lung cancer cells, which plays a role in the development of lung cancer.
|
31572459 |
2019 |
Malignant neoplasm of lung
|
0.800 |
Biomarker
|
disease |
BEFREE |
These results demonstrate a previously unrecognized relationship between p53 and REV3L in cancer cell metabolism and may lead to improvements in chemotherapy treatment plans that reduce cisplatin resistance in lung cancer.
|
29307819 |
2018 |
Malignant neoplasm of lung
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
No other statistically significant differences were determined in the plasma p53 protein level between patients diagnosed with lung cancer exposed and not exposed to radon.
|
29805621 |
2018 |
Malignant neoplasm of lung
|
0.800 |
Biomarker
|
disease |
BEFREE |
RNAi-mediated depletion of eIF2β suppresses growth of lung cancer cells independently of p53 mutation status, in part through G1 cell cycle arrest.
|
29624814 |
2018 |
Malignant neoplasm of lung
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
The positive expression of p53 and MMP-2 in lung cancer tissues before chemotherapy was 76.25 and 71.25%, respectively, and were reduced to 27.50 and 23.75%, respectively, after chemotherapy.
|
30214563 |
2018 |
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).
|
29217530 |
2018 |
Malignant neoplasm of lung
|
0.800 |
Biomarker
|
disease |
BEFREE |
Prognostic value of MAGEA4 in primary lung cancer depends on subcellular localization and p53 status.
|
29901069 |
2018 |
Malignant neoplasm of lung
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
We went on to study the effect of blocking protein aggregation by emodin (1,3,8-trihydroxy-6-methyl-anthraquinone) and figured that inhibiting p53 protein aggregation can elevate the level of autophagy in A549 lung cancer cell line while there is no significant effect on autophagy in normal non-cancerous HaCaT cells.
|
29355754 |
2018 |
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Aim of our study was to evaluate the relationship between the polymorphisms of TP53 pathway genes <i>TP53</i>, <i>MDM2</i>, <i>MDM4</i>, the polymorphisms of HPV-associated genes <i>MTHFR</i>, <i>CASP8</i>, <i>CCR5</i>, and HPV infection with survival of LC patients.SNPs were genotyped using PCR-RFLP. qRT-PCR was used to detect, identify, and quantify HPV.
|
29423041 |
2018 |
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
|
30048458 |
2018 |
Malignant neoplasm of lung
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We also identified apoptosis-related genes enriched with ancestor mutations in lung cancers and a relationship between APC hotspot mutations and TP53 mutations in colorectal cancers.
|
29697365 |
2018 |
Malignant neoplasm of lung
|
0.800 |
Biomarker
|
disease |
BEFREE |
CDK16 Phosphorylates and Degrades p53 to Promote Radioresistance and Predicts Prognosis in Lung Cancer.
|
29344296 |
2018 |
Malignant neoplasm of lung
|
0.800 |
Biomarker
|
disease |
BEFREE |
2-anilino-4-amino-5-aroylthiazole-type compound AS7128 inhibits lung cancer growth through decreased iASPP and p53 interaction.
|
29285847 |
2018 |
Malignant neoplasm of lung
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
To the best of our knowledge it has not been previously reported whether TAp73, p53 and VASH1 are coexpressed in lung cancer.
|
29552154 |
2018 |
Malignant neoplasm of lung
|
0.800 |
Biomarker
|
disease |
BEFREE |
Interaction between the microbiome and TP53 in human lung cancer.
|
30143034 |
2018 |
Malignant neoplasm of lung
|
0.800 |
Biomarker
|
disease |
BEFREE |
These results demonstrate that miR-1269 promotes cell survival and proliferation by targeting TP53 and caspase-9 in lung cancer.
|
29618932 |
2018 |
Malignant neoplasm of lung
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Erastin exposure upregulated and activated p53 and thus, transcriptionally activated its downstream target genes, including p21 and Bax, in lung cancer A549 cells dependent on erastin‑induced ROS.
|
30066882 |
2018 |
Malignant neoplasm of lung
|
0.800 |
Biomarker
|
disease |
BEFREE |
TP53 is frequently involved in lung cancer development with polymorphic sites potentially having a role in it.
|
29286914 |
2018 |
Malignant neoplasm of lung
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
<b>Methods:</b> The expression of HUWE1 and p53 in lung cancer cells was modulated and the phenotypes were assessed by performing soft agar colony forming assays, cell cycle analysis, BrdU incorporation assays, and xenograft tumor growth assays.
|
30026863 |
2018 |
Malignant neoplasm of lung
|
0.800 |
Biomarker
|
disease |
BEFREE |
Computational master-regulator search reveals mTOR and PI3K pathways responsible for low sensitivity of NCI-H292 and A427 lung cancer cell lines to cytotoxic action of p53 activator Nutlin-3.
|
29504919 |
2018 |